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AbstrAct
Objectives High-cost antivascular endothelial growth 
factor (anti-VEGF) medicines for eye disorders challenge 
ophthalmologists and policymakers to provide fair access 
for patients while minimising costs. We describe the 
growth in the use and costs of these medicines and 
measure inequalities in access.
Design Longitudinal study using Hospital Episode 
Statistics (2005/2006 to 2014/2015) and hospital 
prescribing cost reports (2008/2009 to 2015/2016). We 
used Poisson regression to estimate standardised rates 
and explore temporal and geographical variations.
setting National Health Service (NHS) care in England.
Population Patients receiving anti-VEGF injections for 
age-related macular degeneration, diabetic macular 
oedema and other eye disorders.
Interventions Higher-cost drugs (ranibizumab or 
aflibercept) recommended by the National Institute 
for Health and Care Excellence or lower-cost drug 
(bevacizumab) not licensed for eye disorders.
Main outcome measures National procedure rates 
and variation between and within clinical commissioning 
groups (CCGs). Cost of ranibizumab and aflibercept 
prescribing.
results Injection procedures increased by 215% 
between 2010/2011 and 2014/2015. In 2014/2015 
there were 388 031 procedures (714 per 100 000). 
There is no evidence that the dramatic growth in rates 
is slowing down. Since 2010/2011 the estimated cost 
of ranibizumab and aflibercept increased by 247% to 
£447 million in 2015/2016, equivalent to the entire 
annual budget of a CCG. There are large inequalities 
in access; in 2014/2015 procedure rates in a ‘high 
use’ CCG were 9.08 times higher than in a ‘low use’ 
CCG. In the South-West of England there was twofold 
variation in injections per patient per year (range 2.9 
to 5.9).
conclusions The high and rising cost of anti-VEGF 
therapy affects the ability of the NHS to provide care 
for other patients. Current regulations encourage the 
increasing use of ranibizumab and aflibercept rather 
than bevacizumab, which evidence suggests is more 
cost-effective. NHS patients in England do not have equal 
access to the most cost-effective care.
IntrODuctIOn
Clinical commissioning groups (CCGs) 
in England are responsible for commis-
sioning healthcare for a geographically 
defined local population. On average, CCGs 
cover a population of 270 000 and have 
a budget of £300 million to commission 
services including elective and unplanned 
hospital care, and community and mental 
health services. While CCGs have a degree 
of autonomy in the care they commission, 
they must work within national constraints. 
In particular, CCGs must commission new 
interventions which have been evaluated 
to be cost-effective by the National Institute 
for Health and Care Excellence (NICE) 
technology appraisal process. This pres-
ents a challenge as many of these interven-
tions are expensive. A balance is needed 
in order to provide fair access for patients 
eligible for the new interventions without 
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Research
strengths and limitations of this study
 ► Our study summarises new data on nationwide 
access to effective, but high-cost ophthalmology 
drugs.
 ► Using population denominators allows us to 
standardise our analysis for factors, such as age 
and socioeconomic deprivation, which will affect the 
need for care.
 ► The lack of a specific antivascular endothelial growth 
factor drug code in Hospital Episode Statistics is a 
limitation; however we observed similar temporal 
trends in two independent data sources.
 ► The confidential nature of drug discounts mean 
that our estimate of drug costs will be too high 
if commissioners have negotiated substantial 
discounts.
 ► Conversely, the exclusion of administration and 
monitoring costs make our estimates conservative.
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Table 1 National Institute for Health and Care Excellence technology appraisals (TA) for antivascular endothelial growth factor 
therapies
Condition Ranibizumab Aflibercept
Neovascular age-related macular 
degeneration
Recommend 8/2008 (TA 155) Recommend 7/2013 (TA 294)
Diabetic macular oedema Reject 11/2011 (TA 237)
Recommend 2/2013 (TA 274)
Recommend 7/2015 (TA 346)
Retinal vein occlusion Recommend 5/2013 (TA 294) Recommend 2/2014 (TA 305)
Myopic choroidal neovascularisation Recommend 11/2013 (TA 298) Recommend 9/2016 (TA 409)
disadvantaging other patients using existing health 
services.
One recent challenge for CCGs is to commission anti-
vascular endothelial growth factor (anti-VEGF) medicines 
for patients with a range of eye conditions. Anti-VEGF 
intravitreal injections reduce new blood vessel growth 
and swelling.1 Two drugs (ranibizumab and aflibercept) 
are licensed for use in neovascular age-related macular 
degeneration (nAMD), diabetic macular oedema (DMO) 
or retinal vein occlusion (RVO) and myopic choroidal 
neovascularisation (MCNV). Ranibizumab was first 
recommended by NICE as cost-effective for use in nAMD 
in 2008.2 After an initial rejection in 2011, NICE also 
recommended the use of ranibizumab for DMO in 2013 
based on new evidence and an undisclosed discount on 
price offered by the manufacturer.3 Subsequent NICE 
recommendations in other eye conditions and for 
aflibercept have followed (table 1). Ranibizumab and 
aflibercept have a National Health Service (NHS) indic-
ative price in the region of £550 and £800 per injection, 
respectively.4 The high prevalence of these conditions, 
the indefinite need for multiple injections per patient, 
and the associated procedure and monitoring costs mean 
that economic burden is substantial.
In reaching their recommendations, NICE did not 
compare ranibizumab or aflibercept with a pre-existing 
drug, bevacizumab. Bevacizumab also inhibits VEGF 
and is closely related to ranibizumab; it is licensed as a 
treatment for certain types of cancer but not in ophthal-
mology. Bevacizumab can be divided into aliquots of 
smaller doses for ophthalmic therapy and is a much 
less costly alternative (approximately £50 to £100 per 
injection).5 Meta-analysis has demonstrated that beva-
cizumab and ranibizumab result in similar visual acuity 
outcomes for patients with nAMD.6 The CATT and IVAN 
randomised trials of ranibizumab versus bevacizumab 
in nAMD both demonstrated that the drugs resulted in 
similar improvements in visual acuity.7 8 IVAN also found 
that ranibizumab produced little or no gain in quality-ad-
justed life years despite being substantially more expen-
sive.9 Individual patient data meta-analysis indicates that 
the risk of serious adverse events with ranibizumab and 
bevacizumab is similar in nAMD.10 In DMO, the  DRCR. 
net three-arm randomised trial found that aflibercept 
and ranibizumab were not cost-effective relative to 
bevacizumab despite evidence that aflibercept resulted 
in better visual outcomes at 1 years and 2 years, partic-
ularly in those with worse visual acuity at baseline.11 12 
In RVO, the SCORE2 randomised trial concluded that 
bevacizumab was non-inferior to aflibercept for visual 
acuity after 6 months of treatment.13 In 2014, the Royal 
College of Ophthalmologists and others called on UK 
health regulators, including NICE, to urgently review 
the use of bevacizumab in nAMD.14 However, in 2015 
the Department of Health declined to support clini-
cians or commissioners using bevacizumab for nAMD, 
considering unlicensed use ‘on ground of cost alone’ 
as potentially illegal under European Union (EU) law,15 
despite political support for the use of bevacizumab 
for ophthalmic indications in other EU countries such 
as Italy.16 The remit of the forthcoming NICE nAMD 
clinical guidelines preclude making recommendations 
about bevacizumab.17
The emergence of anti-VEGF medicines provides 
ophthalmologists and CCGs with a clinical and economic 
dilemma in both providing fair access for eligible patients 
to drugs recommended by NICE while minimising the 
opportunity costs for other members of the population. 
In this study, we describe the growth in the use and cost of 
anti-VEGF intravitreal injections in the English NHS since 
2005/2006. We quantify the variation in patient access to 
anti-VEGF therapy across England and explore the poten-
tial causes of inequality of access within the South-West 
region of England.
MethODs
Identifying anti-VeGF injections
We used the Hospital Episode Statistics (HES) admitted 
patient care (APC) and outpatient (OP) data sets to 
identify anti-VEGF injections. Anti-VEGF injections are 
performed in OP treatment rooms, but, in earlier years, 
were often coded in the APC data set as day case proce-
dures. HES is a routinely collected data set that records 
all episodes of care provided to NHS-funded and privately 
insured patients admitted (day case or inpatient) to NHS 
hospitals or seen at an NHS OP clinic.18 HES also includes 
data on NHS-funded patients treated in independent 
sector hospitals. We extracted anonymised individual 
episode records on all episodes contained in the HES 
APC (2005/2006 to 2014/2015) and OP (2010/2011 to 
2014/2015) data sets. Up to 24 clinical procedures per 
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Figure 1 Office of Population, Censuses and Surveys 
codes used to identify antivascular endothelial growth factor 
injections: 2014/2015. Note: 2479 eye injection procedures 
were excluded due to combination with X93.2 or X93.3 high-
cost drug codes.
episode may be recorded using the Office of Population, 
Censuses and Surveys (OPCS) (fourth revision) codes.
Anti-VEGF injection procedures are not coded consis-
tently. The majority of healthcare providers used the 
code 'injection into vitreous body, not elsewhere classi-
fied [C79.4]’. In preliminary exploration of HES data we 
looked for negative correlations between this procedure 
code and other ophthalmology procedure codes to iden-
tify potential alternate procedure codes. This identified 
that a substantial minority used a newer code ‘Injection of 
therapeutic substance into posterior segment of eye, not 
elsewhere classified [C89.3]’. HES does not record the 
specific drug injected into the eye; however, since 2009 an 
OPCS code for high-cost subfoveal choroidal neovascular-
isation drugs band 1 (X93.1) has been in use. This code 
may be used for aflibercept, bevacizumab, ranibizumab 
and two other drugs rarely used in intravitreal injections, 
pegaptanib and verteporfin. We excluded any procedures 
using non anti-VEGF drugs (X93.2, X93.3).
In 2014/2015, 73.3% (284 490/388 031) of episodes 
including an eye injection procedure also coded a 
high-cost subfoveal choroidal neovascularisation drug. 
However, some hospitals performing hundreds of intra-
vitreal injections each year never use this high-cost drug 
code. Conversely, 96% (284 490/296 129) of episodes 
coding a high-cost subfoveal choroidal neovascularisation 
drug also included an eye injection procedure (figure 1). 
In our analysis, we assumed that procedures coded as 
C79.4 or C89.3 were anti-VEGF injections. We explore the 
importance of this assumption in our discussion.
A minority of patients receive bilateral injections on the 
same day, which may be coded using the supplemental 
'bilateral operation' (Z94.1) OPCS code. When a patient 
had a bilateral procedure coded, we counted this as two 
injection procedures. When a patient had two injection 
procedures coded on the same day without any supple-
mental bilateral code, we assumed that this also repre-
sented bilateral procedures. If patients had more than two 
injection procedures coded on the same day, we excluded 
the 'excess' procedures as probable coding error dupli-
cates (<0.03% of all procedures).
We used International Classification of Diseases 10th 
revision (ICD-10) diagnosis codes to identify patients with 
diabetes with ophthalmic complications (E10.3, E11.3, 
E12.3, E13.3 or E14.3) or diabetic retinopathy (H36.0) 
or with a primary code indicating ‘other specified retinal 
disorders’ (H35.8) combined with secondary codes indi-
cating diabetes with ophthalmic complications as above; 
nAMD (H35.3); RVO (H34.8); and MCNV (H44.2), 
respectively. Diagnosis codes are well recorded for proce-
dures in the HES APC data set, however in the HES OP 
data set diagnosis codes are often missing. Therefore, we 
limited our analysis of diagnostic indications to proce-
dures recorded in the HES APC data set.
estimating procedure rates
National trends over time were estimated using directly 
standardised procedure rates19 (per 100 000 population), 
with the population of England in 2014 as our standard 
population. We first summed the number of anti-VEGF 
injections, grouped by sex, quintiles of age and finan-
cial year. These procedure counts were used to calculate 
annual age-sex-specific rates, by dividing by the appro-
priate age-sex-specific midyear populations of England20 
(eg, for the 2012/2013 financial year, the mid-2012 popu-
lations were used). We weighted the annual age-sex-spe-
cific rates according to the population distribution of 
England in 2014, to produce directly standardised rates 
for each year.
Patients typically have more than one injection proce-
dure in a year. Variation in patient access to anti-VEGF 
injections within England might be evident in both the 
number of patients treated and the number of proce-
dures performed. Therefore, we estimated indirectly stan-
dardised rates19 per 100 000 population for both patients 
and procedures. We first calculated age-sex-specific rates 
for England in 2014/2015, then multiplied these rates by 
the age-sex-specific population for the area of interest20–22 
(eg, CCG) and summed the results. This produced the 
expected number of patients and procedures for that 
area, if it were to have the same age-sex-specific rates 
as England. The expected number was then compared 
with the observed number of patients and procedures for 
that area. A Poisson regression model was fitted to the 
observed counts, with the expected counts as an offset 
and socioeconomic deprivation (using the overall score 
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Figure 2 Directly standardised intravitreal injection 
procedure rates, England, 2005/2006–2014/2015. APC, 
admitted patients care; HES, Hospital Episode Staristics; OP, 
outpatient.
Figure 3 Percentage of total eye injection procedures 
in Hospital Episode Statistics admitted patients care 
for different primary diagnoses, England, 2008/2009–
2014/2015. AMD, age-related macular degeneration; 
RVO, retinal vein occlusion; due to very small numbers of 
procedures for myopic choroidal neovascularisation (≤10 per 
year), this was included in ‘Other’.from the English Indices of Multiple Deprivation23) and 
ethnicity (% white British24) as predictive factors. The 
model was then used to predict new expected counts for 
each area based on deprivation and ethnicity, and form 
indirectly standardised patient and procedure ratios 
(observed/expected). Statistical analyses were conducted 
using Stata/MP V.14.2 for Windows and we mapped vari-
ation in patient and procedure rates across England in 
2014/2015 using ArcGIS ArcMap V.10.3.1 for Desktop.
exploring variation in access in the south-West region of 
england
For each CCG in the South-West region of England we 
estimated the median age and gender proportion in order 
to explore any differences in the demographic profile of 
patients receiving anti-VEGF injections. We estimated the 
annual number of procedures per patient in 2014/2015 
to determine whether CCGs with high patient rates also 
had a higher number of procedures per patient. We also 
calculated and mapped indirectly standardised proce-
dure ratios between Middle Layer Super Output Areas to 
explore whether CCG boundaries or hospital catchment 
areas were more strongly associated with access to anti-
VEGF injections.
estimating the cost of anti-VeGF injections
We extracted data from NHS Digital Hospital prescribing 
costs reports25 in order to estimate the costs of ranibi-
zumab and aflibercept since 2008/2009 when ranibi-
zumab was first approved by NICE. The NHS digital 
report summarises data collected from English NHS 
hospital pharmacies by the IMS Health Hospital Pharmacy 
Audit Index (HPAI). This includes high-cost medicines 
supplied to wards, OP clinics and satellite sites. Costs are 
reported in the HPAI and are calculated by IMS Health 
using standard price lists and therefore do not necessarily 
reflect any discounted prices paid by hospitals. Anti-VEGF 
therapy also incurs administration and monitoring costs; 
however, the IVAN trial indicated that, in the ranibizumab 
group, drug costs accounted for 80%–88% of total costs.9 
Injection frequency and monitoring visits may be lower 
for aflibercept where fixed 2-monthly interval dosing is 
recommended after an initial period of monthly loading 
doses.
Bevacizumab is not included in HPAI and due to the 
lack of drug coding in HES data it is impossible to accu-
rately estimate the current use of bevacizumab for eye 
conditions. A study in 2015 based on 189 Freedom of 
Information requests across the UK estimated the relative 
prevalence of injections of ranibizumab, aflibercept and 
bevacizumab to be 61.1%, 36.0% and 2.8%, respectively.26
results
the use and cost of anti-VeGF intravitreal injections
In 2014/2015 there were 388 031 intravitreal injection 
procedures, equivalent to 714 procedures per 100 000 
population (figure 2). This compares to 123 006 proce-
dures in 2010/2011 and represents a 215% increase in 
the number of procedures over the 5-year period. Before 
2007, intravitreal injections were rarely used. The rise in 
procedure rates since then is dramatic and there are no 
signs that it is levelling off.
Among episodes recorded in the HES APC data set, 
the majority (62% in 2014/2015) had diagnosis codes 
indicating nAMD (figure 3). The relative use of diag-
nosis codes indicating DMO or RVO show small recent 
increases associated with NICE approvals for these indi-
cations in 2013. The estimated total cost of hospital 
prescribing of ranibizumab and aflibercept increased 
by 197% from £129 million to £383 million in the 5 years 
between 2010/2011 and 2014/2015 (figure 4). The esti-
mated total cost of ranibizumab and aflibercept had risen 
to £447 million in 2015/2016, predominantly due to the 
increasing use of aflibercept.
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Figure 4 Hospital prescribing costs for ranibizumab and aflibercept, 2008/2009 to 2015/2016.
Figure 5 (A) Indirectly age-sex-deprivation-ethnicity standardised procedure ratios for combined eye injection procedures 
(OPCS-4: C794 and C893) by CCG in England, 2014/2015. (B) Indirectly age-sex-deprivation-ethnicity standardised patient 
ratios for combined eye injection procedures (OPCS-4: C794 and C893) by CCG in England, 2014/2015. CCG,  clinical 
commissioning group; OPCS, Office of Population, Censuses and Surveys.
Variation in patient access to anti-VeGF therapy
In 2014/2015 there was substantial variation in proce-
dure rates between CCGs, even after adjusting for age, 
sex, deprivation and ethnicity profiles (figure 5A). The 
map demonstrates pockets of very high use (>150% times 
the expected rate), for example, in the Bristol area and in 
parts of North London and Norfolk. There are also areas 
where procedure rates are less than 50% of the expected 
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rate, for example, in parts of Essex. There was less 
pronounced, but still substantial variation in patient rates 
between CCGs, after adjusting for age, sex, deprivation 
and ethnicity profiles (figure 5B). Areas of the country 
with high procedure rates also tended to have higher 
proportions of their populations having treatment. In 
2014/2015 the ratio in patient rates between a 'high use' 
CCG at the 90th centile and a 'low use' CCG at the 10th 
centile was 4.98. This ratio has only slightly decreased 
since 2010/2011, when the ratio was 6.07, indicating that 
equality of access to care is only slowly improving over 
time.
Examining the South-West region of England in more 
detail (figure 6A,B), it is evident that there is substantial 
variation in access to anti-VEGF injections within CCGs. 
For example, in both Somerset and Wiltshire there are 
areas of relatively high procedure rates closer to the 
major conurbations of Bath, Bristol and Swindon. Proce-
dure rates are much lower than expected in other areas 
of these CCGs, even though these other areas are served 
by local hospitals. The age and gender profiles of patients 
receiving anti-VEGF therapy were similar between CCGs 
(table 2). Median age ranged from 77 years to 82 years 
and between 39% and 49% of patients were male. There 
was twofold variation in the number of procedures per 
patient per year ranging from 2.9 in Cornwall to 5.9 in 
South Gloucestershire. The standardised CCG patient 
rate was strongly correlated with the number of proce-
dures per patient (Spearman’s ρ=0.71, p<0.001).
DIscussIOn
statement of principal findings
There is no evidence that the dramatic growth in the use of 
high-cost anti-VEGF injections in ophthalmology is slowing 
down. Injection procedures increased by 215% between 
2010/2011 and 2014/2015. There are large inequalities in 
access to anti-VEGF therapy. This inequality is not explained 
by differences in demographics and occurs both within and 
between CCGs. Procurement of high-cost anti-VEGF drugs 
has placed a large and increasing strain on the NHS. In 
2015/2016, the NHS spent an estimated £447 million on 
drug costs alone, equivalent to the entire annual budget of 
a large CCG.
strengths and weaknesses of the study
Our study summarises new data on nationwide access to 
effective but high-cost ophthalmology drugs. Using popula-
tion denominators allows us to standardise our analysis for 
factors, such as age and socioeconomic deprivation, which 
will affect the need for care. HES data record patients' 
area of residence, so we compare access based on place 
of residence rather than place of treatment. The combi-
nation of HES APC and OP data sets is essential in order 
to accurately monitor intravitreal injections over time. As 
reimbursement payments depend on procedure coding, 
there is an incentive for providers to fully code procedures. 
However, the lack of a specific anti-VEGF drug code in HES 
is a limitation. Other similar procedures such as the intra-
vitreal injection of dexamethasone implants have distinct 
OPCS procedure codes, although we cannot exclude the 
possibility of miscoding. We observed similar temporal 
trends in two independent data sources measuring proce-
dures (ie, HES) and drug costs (ie, HPAI), which provides 
reassurance about the validity of our time-trend analyses. 
Previous work has demonstrated that HES generally has 
good sensitivity in identifying new procedures, but may lack 
specificity, particularly in the absence of a single specific 
procedure code.27 It is plausible that drug price discounts 
account for some of the observed variations, if CCGs who 
have larger discounts offer more therapy. The confiden-
tial nature of discounts means that our estimate of drug 
costs will be too high if CCGs have negotiated substantial 
discounts. Conversely, the exclusion of administration and 
monitoring costs makes our estimates conservative and 
there is a substantial economic burden for patients. Travel 
and postappointment recovery time have a large impact 
on patients and carers.28 The costs of all three anti-VEGF 
drugs will be offset, to a greater or lesser extent, in the 
longer term by reduced need for NHS and social services 
related to vision loss.
comparison with other studies
Between 1989/1990 and 2008/2009, Keenan et al observed 
an increase in intravitreal injection rates from 0.4 per 
1 00 000 to 59.5 per 100.000 with wide variations in access 
between different local authorities in England.29 Our data 
demonstrate that this rapid growth has continued and even 
accelerated in the following 6 years. We were also able to 
explore variation in access to care at a more granular level 
and demonstrate that access varies markedly both within 
and between CCGs, suggesting that variations are likely 
to be due, at least in part, to the availability of trained 
staff (eg, ophthalmologists and nurse practitioners) and 
facilities in local hospitals rather than CCG-wide policies. 
Using insurance data, Parikh et al observed a continually 
increasing trend in anti-VEGF use in the USA between 
2006 and 2015.30 In line with our study, Parikh et al also 
found that anti-VEGF drug use was predominantly for 
nAMD. It is impossible to directly compare England 
and US rates as the denominator used in the Parikh et al 
study excludes patients without commercial or Medicare 
Advantage insurance. However, anti-VEGF therapy rates 
in the USA and UK appear to be of the same order of 
magnitude. Specific coding of anti-VEGF drugs allowed 
Parikh et al to document the rise in the use of aflibercept 
(28% of all anti-VEGF injections in 2015) and the concur-
rent levelling off in the use of ranibizumab (17%) and 
bevacizumab (55%). This is in stark contrast to England 
where ranibizumab and aflibercept predominate. This is 
likely to be a result of legal challenges to the use of beva-
cizumab and the lack of Department of Health support 
for commissioners.31
Implications for policymakers and clinicians
Based on the IVAN trial, Dakin et al estimated that the 
NHS could save £102 million per year by switching from 
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Figure 6 (A) Indirectly standardised procedure ratios for combined eye injection procedures by Middle Layer Super Output 
Areas (MSOA) in SW England, 2014/2015. (B) Indirectly standardised patient ratios for combined eye injection procedures 
by MSOA in SW England, 2014/2015. Note: Major hospitals marked including those in National Health Service (NHS) Trusts 
providing 100+ procedures. CCG, clinical commissioning group.
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Table 2 Demographics of anti-VEGF procedures in South-West CCGs, 2014/2015; ordered by procedures per patient
CCG Name
% 
Male
Median 
age
Procedures per 
patient (95% CI)
Procedure rate* 
(95% CI†)
Patient rate* 
(95% CI)
NHS Kernow CCG 43 79 2.86 (2.75 to 2.97) 522 (490 to 556) 172 (191 to 104)
NHS Dorset CCG 43 82 3.32 (3.21 to 3.43) 419 (394 to 445) 122 (136 to 74)
NHS Herefordshire CCG 38 80 3.34 (3.14 to 3.53) 631 (569 to 700) 175 (210 to 110)
NHS Somerset CCG 45 78 3.48 (3.27 to 3.68) 304 (276 to 334) 92 (106 to 57)
NHS South Warwickshire CCG 44 79 3.63 (3.46 to 3.8) 773 (708 to 844) 206 (240 to 128)
NHS Oxfordshire CCG 40 81 3.63 (3.5 to 3.76) 723 (679 to 771) 197 (220 to 120)
NHS Northern-Eastern and Western Devon CCG 41 81 4.05 (3.95 to 4.16) 830 (792 to 869) 201 (218 to 121)
NHS Newbury and district CCG 41 79 4.14 (3.72 to 4.55) 637 (530 to 764) 136 (186 to 92)
NHS Wiltshire CCG 46 79 4.17 (3.95 to 4.39) 459 (419 to 502) 103 (121 to 64)
NHS South Devon and Torbay CCG 40 81 4.2 (4.05 to 4.35) 923 (860 to 991) 206 (235 to 127)
NHS South Worcestershire CCG 42 79 4.36 (4.16 to 4.56) 875 (806 to 950) 188 (217 to 116)
NHS Bath and North-East Somerset CCG 49 81 4.44 (4.14 to 4.73) 735 (650 to 831) 152 (189 to 97)
NHS Swindon CCG 44 77 4.54 (4.26 to 4.82) 1034 (928 to 1153) 216 (260 to 137)
NHS West Hampshire CCG 42 80 5 (4.85 to 5.15) 1125 (1063 to 1190) 221 (244 to 133)
NHS North Somerset CCG 43 80 5.43 (5.15 to 5.71) 1236 (1130 to 1352) 217 (253 to 135)
NHS Bristol CCG 43 80 5.49 (5.26 to 5.72) 1346 (1248 to 1451) 237 (270 to 146)
NHS Gloucestershire CCG 42 81 5.51 (5.33 to 5.68) 1263 (1194 to 1336) 226 (249 to 137)
NHS South Gloucestershire CCG 46 79 5.93 (5.65 to 6.22) 1379 (1264 to 1505) 222 (258 to 138)
* Procedure rate and patient rate are the indirectly standardised rates per 100 000 population.
†95% CIs on the procedure rate are calculated using Stukel et al’s method for recurrent outcomes.40
anti-VEGF, antivascular endothelial growth factor; CCG, clinical commissioning group; NHS, National Health Service.
ranibizumab to bevacizumab.9 In the USA, Hutton et 
al estimated that a similar switch would save Medicare 
$18 billion over a 10-year period.32 Given the lack of polit-
ical and regulatory support for clinicians to use bevaci-
zumab, it is unsurprising that most in England do not use 
it. This has led to the very unusual situation whereby NHS 
is paying for more expensive therapy than healthcare 
insurers in the USA. The patent on ranibizumab is due 
to expire in Europe in 2022;33 in the meantime, based 
on current trends, NHS may spend billions on anti-VEGF 
injections, before biosimilar drugs become available. Our 
data, demonstrating large variations between CCGs in the 
numbers of patients accessing anti-VEGF services, also 
suggest that there is considerable potential unmet need 
in some areas of the country. Given that many CCGs are 
already in financial deficit, most will struggle to afford to 
treat more patients unless they are able to switch to beva-
cizumab. The political decision not to support NHS use 
of bevacizumab in eye conditions is in stark contrast to 
decisions taken in other EU countries16 and has very large 
negative consequences for NHS patients.
In April 2017, NICE introduced a budget impact test 
for new technologies under appraisal that are expected 
to cost more than £20 million per annum. This allows 
NHS England up to 3 years to conduct commercial nego-
tiations on price rather than the current requirement to 
fund within 90 days.34 This policy should strengthen the 
future negotiating power of the NHS for expensive drugs. 
However, it does not address the fundamental problem 
that NICE has not included cost-effective but unlicensed 
drugs in technology appraisals or clinical guideline 
recommendations.
The widespread variation in procedure rates that we 
observed might be due to travel distance affecting patient 
access to diagnostic and therapeutic services, particularly 
in more remote areas. Lengthy travel distance is associ-
ated with treatment discontinuance.35 However, many of 
the low injection rate areas in the South-West of England 
are close to hospitals. Other unmeasured factors, such 
as the importance of vision for work or usual activities, 
may also be associated with patient uptake and compli-
ance with anti-VEGF therapy. The frequency of injections 
per patient per year was lower than reported in trials of 
therapy initiation. The averages in our study will be drawn 
downwards due to patients starting and discontinuing 
therapy partway through the year and by patients who 
have been on anti-VEGF therapy for many years and need 
fewer injections.
unanswered questions and future research
Given the high cost of the drugs, it is imperative that 
clinical services are organised to deliver care efficiently. 
For example, nurse-administered injections,36 treat and 
extend protocols,37 optometrist-led monitoring38 and 
stereotactic radiotherapy,39 all offer the potential to 
reduce costs and require stronger evidence. The wide 
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variation between CCGs in the number of injections per 
patient represents a natural experiment. Observational 
studies could compare costs and outcomes between areas 
of the country with high and low injection frequencies. 
However, the lack of a nationwide register of patients 
receiving anti-VEGF injections and the lack of drug 
coding in HES severely limit the potential to conduct this 
research.
cOnclusIOns
Anti-VEGF therapy is effective in most cases and has 
improved the quality of life of many thousands of patients 
in England. However, current regulations encourage the 
increasing use of ranibizumab and aflibercept rather 
than bevacizumab, which, evidence suggests, is more 
cost-effective. This limits the ability of NHS to pay for care 
for other patients. NHS patients in England do not have 
equal access to the most cost-effective care.
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